Tag archives: TJC

Urgent New Survey Standards From The Joint Commission Address Aisle Widths and CAH Suites

By Yvonne Puig (US), Daphne Calderon (US) and Jeff Wurzburg (US) on April 23, 2021 Posted in Coronavirus, General

This week The Joint Commission (“TJC”) announced new requirements that are effective immediately and require suites to have aisles with at least “36 inches of clearance from side to side to facilitate egress.” The standard aligns with the National Fire Protection Association’s (FPA) Life Safety Code and is applicable to hospitals accredited by TJC and … Continue reading

COVID-19 Update: The Joint Commission to Resume Hospital Surveys

By Yvonne Puig (US), Daphne Calderon (US) and Jeff Wurzburg (US) on June 10, 2020 Posted in Coronavirus, General, Regulatory

The Joint Commission (TJC) is resuming regular surveys and reviews after suspending them at the outset of the COVID-19 pandemic. Safety will be “the first and foremost priority” as surveys and reviews are resumed and the survey’s will “assess the impact that the coronavirus pandemic had on their operations and their current state.” The surveys … Continue reading

The Joint Commission releases sentinel event statistics for first six Months of 2019

By Yvonne Puig (US) and Jeff Wurzburg (US) on August 15, 2019 Posted in Regulatory

On August 14, 2019 The Joint Commission (TJC) released sentinel event statistics for the first half of 2019, which included 426 events. 83% of the events were voluntarily self-reported by an accredited or certified organization. The five most frequently reported sentinel events were: Unintended retention of a foreign body part – 60 Wrong-site surgery – … Continue reading

The Joint Commission Issues Sentinel Event Alert on Direct Oral Anticoagulants

By Yvonne Puig (US) and Jeff Wurzburg (US) on July 31, 2019 Posted in Regulatory

On July 30, 2019, The Joint Commission (TJC) issued Sentinel Event Alert 61: Managing the risks of direct oral anticoagulants (“DOACs”). The alert may be found here. According to TJC, “anticoagulants have been named second of the top medications involved in error incidents causing death or serious harm.” Because there are not FDA-approved reversal agents … Continue reading